Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia. (SCADOLII)
Primary Purpose
Acute Coronary Syndrome
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
MEOPA and paracetamol
Morphine
Sponsored by

About this trial
This is an interventional treatment trial for Acute Coronary Syndrome focused on measuring premixed nitrous oxide and oxygen, pain, prehospital setting, acute coronary syndrome
Eligibility Criteria
Inclusion Criteria:
- Patient with STEMI < 12 h treated before hospital admission and pain ≥ 4 on the numerical rating scale.
Exclusion Criteria:
- Acute severe hemodynamic, respiratory or neurological failure
- Heart failure: Killip class III and IV
- Known allergy to morphine or nitrous oxide
- Patient who has already received morphine or MEOPA before the arrival of the hospital team during the 4 hours preceding the pre-hospital intervention
- Contraindications to nitrous oxide
- Patient unable to assess pain intensity on the numerical rating scale
- Patient under legal guardianship
- Pregnancy
- Patient transported by air ambulance
Sites / Locations
- Centre Hospitalier d'Agen
- Centre Hospitalier Jean Minjoz
- CHU Avicenne
- Hôpital Pellegrin
- Centre Hospitalier Bourg-en-Bresse
- Centre Hospitalier de Chambéry
- Centre Hospitalier Louis Pasteur
- Centre Hospitalier Chateauroux
- CHU d'Estaing
- Centre Hospitalier Beaujon
- Centre Hospitalier Alpes Léman
- Centre Hospitalier Sud Francilien
- Centre Hospitalier Dijon
- Centre Hospitalier du Val d'Ariège
- Centre Hospitalier Raymond Poincaré
- Centre Hospitalier de Grenoble
- Centre Hospitalier Départemental La Roche/Yon
- CHRU Lille
- CHU Dupuytren
- Centre Hospitalier Edouard Herriot
- Centre Hospitalier de la Timone
- Centre Hospitalier Marc Jacquet
- CHR Bon Secours
- CHRU Montpellier
- CHU Nancy
- CHU Nantes
- Centre Hospitalier de Nice
- Centre Hospitalier Necker
- Centre Hospitalier Pitié-Salpétrière
- Groupe hospitamier Lariboisière-Fernand Widal-St-Louis
- CHU Poitiers
- Centre Hospitalier René Dubos
- Centre Hospitalier Annecy-Gennevois
- Centre Hospitalier Comminges Pyrénées
- Centre Hospitalier Poulon la Seyne-sur-mer
- CHU Toulouse
- CHRU Tours
- Centre Hospitalier de Valence
- Centre Hospitalier Lucien Hussel
- CHU Félix Guyon
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Morphine
MEOPA and paracetamol
Arm Description
Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation. During the same time, an intravenous injection of 1 g paracetamol will be administered.
Outcomes
Primary Outcome Measures
Effective analgesia (NRS score≤ 3) at 30 minutes after the start of analgesia
The primary outcome measure is effective analgesia, defined by the consensus conference as an NRS score ≤ 3 at 30 minutes after the start of analgesia.
Secondary Outcome Measures
Adverse event
Occurrence of an adverse effect, in particular, respiratory depression (RR, respiratory rate < 10 cycles par minute or respiratory score ≥ R1), nausea, vomiting, sedation (sedation scale (EDS) score ≥2), dizziness, pruritus.
NRS distribution
Distribution of the NRS at 30 minutes and on arrival at the cardiology unit
Effective analgesia
The time of effective analgesia will be defined for each subject
Full Information
NCT ID
NCT02198378
First Posted
July 22, 2014
Last Updated
February 2, 2018
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT02198378
Brief Title
Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.
Acronym
SCADOLII
Official Title
Analgesia of Acute Coronary Syndromes With ST-segment Elevation in a Pre-hospital Setting. Randomized Non-inferiority Trial of the Association MEOPA + Paracetamol Versus Morphine.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
November 2014 (Actual)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In the management of acute coronary syndromes with ST-segment elevation (STEMI), early analgesia reduces the effects of hyperadrenalism which increases the size of myocardial infarction. In order to reduce pain intensity, the recommendations advocate emergency use of morphine. In STEMI patients, other analgesic treatments could provide analgesia that is at least as effective as morphine. The equimolar oxygen/nitrous oxide mixture (MEOPA) is widely used in emergency medicine and has minor secondary effects that are very rapidly reversible when inhalation is discontinued. Used in association with paracetamol, it could be an at least equally effective alternative to the use of morphine.
Detailed Description
The investigators wish to compare the use of morphine according to current recommendations with the use of MEOPA associated with intravenous paracetamol in the management of patients with STEMI. The investigators hypothesize that the association of MEOPA and paracetamol, which is easy to use in a pre-hospital setting, will give patients pain relief as effectively as morphine.
This alternative treatment would avoid the use of morphine, whose potentially damaging consequences on myocardial function have been suggested by experimental studies and by an observational study. The physician of the mobile emergency team (SMUR) verifies the inclusion and non- inclusion criteria for the study. The patient must present STEMI defined in accordance with the recommendations and chest pain of intensity ≥ 4 on the NRS. The specific treatment for STEMI will be given before inclusion in the study, with the exception of analgesic treatment. In particular, inclusion in the study must not delay the initiation of strategies of recanalization and reperfusion.
The SMUR physician in charge of the patient will administer the treatment defined by randomization.
After 30 minutes, the patient will be managed in accordance with the recommendations and will be hospitalized, generally in a cardiology intensive care unit. At one month, the clinical research technician will record the patient's vital status and collect the patient's hospital records.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome
Keywords
premixed nitrous oxide and oxygen, pain, prehospital setting, acute coronary syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
680 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Morphine
Arm Type
Active Comparator
Arm Description
Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
Arm Title
MEOPA and paracetamol
Arm Type
Experimental
Arm Description
The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation.
During the same time, an intravenous injection of 1 g paracetamol will be administered.
Intervention Type
Drug
Intervention Name(s)
MEOPA and paracetamol
Other Intervention Name(s)
Entonox 170 bar
Intervention Description
The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
Intervention Type
Drug
Intervention Name(s)
Morphine
Other Intervention Name(s)
Morphine Renaudin 1mg/ml
Intervention Description
Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
Primary Outcome Measure Information:
Title
Effective analgesia (NRS score≤ 3) at 30 minutes after the start of analgesia
Description
The primary outcome measure is effective analgesia, defined by the consensus conference as an NRS score ≤ 3 at 30 minutes after the start of analgesia.
Time Frame
30 minutes after randomisation.
Secondary Outcome Measure Information:
Title
Adverse event
Description
Occurrence of an adverse effect, in particular, respiratory depression (RR, respiratory rate < 10 cycles par minute or respiratory score ≥ R1), nausea, vomiting, sedation (sedation scale (EDS) score ≥2), dizziness, pruritus.
Time Frame
all 5 minutes during 30 minutes
Title
NRS distribution
Description
Distribution of the NRS at 30 minutes and on arrival at the cardiology unit
Time Frame
30 minutes after randomization
Title
Effective analgesia
Description
The time of effective analgesia will be defined for each subject
Time Frame
all 5 minutes during 30 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with STEMI < 12 h treated before hospital admission and pain ≥ 4 on the numerical rating scale.
Exclusion Criteria:
Acute severe hemodynamic, respiratory or neurological failure
Heart failure: Killip class III and IV
Known allergy to morphine or nitrous oxide
Patient who has already received morphine or MEOPA before the arrival of the hospital team during the 4 hours preceding the pre-hospital intervention
Contraindications to nitrous oxide
Patient unable to assess pain intensity on the numerical rating scale
Patient under legal guardianship
Pregnancy
Patient transported by air ambulance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandrine Charpentier, PH,MD
Organizational Affiliation
CHU Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier d'Agen
City
Agen
Country
France
Facility Name
Centre Hospitalier Jean Minjoz
City
Besançon
Country
France
Facility Name
CHU Avicenne
City
Bobigny
Country
France
Facility Name
Hôpital Pellegrin
City
Bordeaux
Country
France
Facility Name
Centre Hospitalier Bourg-en-Bresse
City
Bourg-en-Bresse
Country
France
Facility Name
Centre Hospitalier de Chambéry
City
Chambéry
Country
France
Facility Name
Centre Hospitalier Louis Pasteur
City
Chartres
Country
France
Facility Name
Centre Hospitalier Chateauroux
City
Chateauroux
Country
France
Facility Name
CHU d'Estaing
City
Clermont-Ferrand
Country
France
Facility Name
Centre Hospitalier Beaujon
City
Clichy
Country
France
Facility Name
Centre Hospitalier Alpes Léman
City
Contamine sur Arve
Country
France
Facility Name
Centre Hospitalier Sud Francilien
City
Corbeil-Essonnes
Country
France
Facility Name
Centre Hospitalier Dijon
City
Dijon
Country
France
Facility Name
Centre Hospitalier du Val d'Ariège
City
Foix
Country
France
Facility Name
Centre Hospitalier Raymond Poincaré
City
Garches
Country
France
Facility Name
Centre Hospitalier de Grenoble
City
Grenoble
Country
France
Facility Name
Centre Hospitalier Départemental La Roche/Yon
City
La Roche-sur-Yon
Country
France
Facility Name
CHRU Lille
City
Lille
Country
France
Facility Name
CHU Dupuytren
City
Limoges
Country
France
Facility Name
Centre Hospitalier Edouard Herriot
City
Lyon
Country
France
Facility Name
Centre Hospitalier de la Timone
City
Marseille
Country
France
Facility Name
Centre Hospitalier Marc Jacquet
City
Melun
Country
France
Facility Name
CHR Bon Secours
City
Metz
Country
France
Facility Name
CHRU Montpellier
City
Montpellier
Country
France
Facility Name
CHU Nancy
City
Nancy
Country
France
Facility Name
CHU Nantes
City
Nantes
Country
France
Facility Name
Centre Hospitalier de Nice
City
Nice
Country
France
Facility Name
Centre Hospitalier Necker
City
Paris
Country
France
Facility Name
Centre Hospitalier Pitié-Salpétrière
City
Paris
Country
France
Facility Name
Groupe hospitamier Lariboisière-Fernand Widal-St-Louis
City
Paris
Country
France
Facility Name
CHU Poitiers
City
Poitiers
Country
France
Facility Name
Centre Hospitalier René Dubos
City
Pontoise
Country
France
Facility Name
Centre Hospitalier Annecy-Gennevois
City
Pringy
Country
France
Facility Name
Centre Hospitalier Comminges Pyrénées
City
Saint-Gaudens
Country
France
Facility Name
Centre Hospitalier Poulon la Seyne-sur-mer
City
Toulon
Country
France
Facility Name
CHU Toulouse
City
Toulouse
Country
France
Facility Name
CHRU Tours
City
Tours
Country
France
Facility Name
Centre Hospitalier de Valence
City
Valence
Country
France
Facility Name
Centre Hospitalier Lucien Hussel
City
Vienne
Country
France
Facility Name
CHU Félix Guyon
City
Saint-Denis
Country
Réunion
12. IPD Sharing Statement
Citations:
PubMed Identifier
21237321
Citation
Danchin N, Puymirat E, Aissaoui N, Adavane S, Durand E. [Epidemiology of acute coronary syndromes in France and in Europe]. Ann Cardiol Angeiol (Paris). 2010 Dec;59 Suppl 2:S37-41. doi: 10.1016/S0003-3928(10)70008-1. French.
Results Reference
background
PubMed Identifier
10973764
Citation
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000 Sep;21(18):1502-13. doi: 10.1053/euhj.2000.2305.
Results Reference
background
PubMed Identifier
17569677
Citation
Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology; Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 Jul;28(13):1598-660. doi: 10.1093/eurheartj/ehm161. Epub 2007 Jun 14. No abstract available.
Results Reference
background
PubMed Identifier
19004841
Citation
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12. No abstract available.
Results Reference
background
PubMed Identifier
18191746
Citation
Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association; Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Pearle DL, Sloan MA, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008 Jan 15;51(2):210-47. doi: 10.1016/j.jacc.2007.10.001. No abstract available. Erratum In: J Am Coll Cardiol. 2008 Mar 4;51(9):977.
Results Reference
background
PubMed Identifier
32398160
Citation
Charpentier S, Galinski M, Bounes V, Ricard-Hibon A, El-Khoury C, Elbaz M, Ageron FX, Manzo-Silberman S, Soulat L, Lapostolle F, Gerard A, Bregeaud D, Bongard V, Bonnefoy-Cudraz E; SCADOL II investigators. Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocardial infarction: open-label, cluster-randomized, non-inferiority study. Scand J Trauma Resusc Emerg Med. 2020 May 12;28(1):36. doi: 10.1186/s13049-020-00731-y.
Results Reference
derived
Learn more about this trial
Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.
We'll reach out to this number within 24 hrs